Antithrombotic therapy in patients with diabetes mellitus
- 作者: Kryukov E.1, Kuchmin A.1, Umanskaya E.1, Nagorny M.1, Shevelev A.1, Rozhkova A.1
-
隶属关系:
- Military Medical Academy of S.M. Kirov
- 期: 卷 24, 编号 4 (2022)
- 页面: 737-750
- 栏目: Review
- URL: https://journals.rcsi.science/1682-7392/article/view/134074
- DOI: https://doi.org/10.17816/brmma108793
- ID: 134074
如何引用文章
详细
The study discussed various possibilities of antithrombotic therapy in patients with diabetes mellitus. Patients with diabetes mellitus, regardless of whether they have cardiovascular diseases, have a high risk of thrombosis. A feature of the response to antiplatelet therapy is the higher resistance to acetylsalicylic acid and clopidogrel of patients with diabetes mellitus than patients without diabetes mellitus, which can reach 71.4% and 57.1%, respectively. With a decrease in the functional ability of the kidneys in patients with diabetic nephropathy, acetylsalicylic acid is a safe antiplatelet drug; the use of clopidogrel in these patients leads to an increase in the risk of general and cardiovascular mortality. In the absence of contraindications, acetylsalicylic acid is recommended for patients with diabetes mellitus for the secondary prevention of cardiovascular diseases and may be recommended for primary prevention in patients with high and very high cardiovascular risk. Clopidogrel is recommended for patients with diabetes mellitus only for the secondary prevention of intolerance to acetylsalicylic acid. With the development of acute coronary syndrome, patients with diabetes mellitus received double antiplatelet therapy using acetylsalicylic acid and any P2Y12 receptor blocker. In patients who received percutaneous coronary intervention, prasugrel or ticagrelor is recommended as the second component. Double antiplatelet therapy extended for >12 months is indicated for patients with diabetes mellitus with a very high cardiovascular risk and good tolerability. In non-valvular atrial fibrillation, direct oral anticoagulants, in the absence of contraindications, are the drugs of choice in patients with diabetes and creatinine clearance > 30 mL/min for dabigatran and > 15 mL/min for rivaroxaban and apixaban. With the development of terminal renal insufficiency, only warfarin has proven effectiveness. Combined antiplatelet and anticoagulant therapy is indicated for diabetes mellitus with coexisting atherosclerotic diseases with a high risk of thrombotic and low risk of hemorrhagic complications.
作者简介
Evgeniy Kryukov
Military Medical Academy of S.M. Kirov
Email: ilikedm@mail.ru
ORCID iD: 0000-0002-8396-1936
SPIN 代码: 3900-3441
Scopus 作者 ID: 57208311867
Researcher ID: AAO-9491-2020
doctor of medical sciences, professor
俄罗斯联邦, Saint PetersburgAlexey Kuchmin
Military Medical Academy of S.M. Kirov
Email: ilikedm@mail.ru
ORCID iD: 0000-0003-2888-9625
SPIN 代码: 7787-1364
doctor of medical science, professor
俄罗斯联邦, Saint PetersburgElena Umanskaya
Military Medical Academy of S.M. Kirov
Email: elenaumansk@mail.ru
SPIN 代码: 2690-3373
candidate of medical sciences
俄罗斯联邦, Saint PetersburgMikhail Nagorny
Military Medical Academy of S.M. Kirov
编辑信件的主要联系方式.
Email: ilikedm@mail.ru
SPIN 代码: 1861-8100
candidate of medical sciences
俄罗斯联邦, Saint PetersburgAndrey Shevelev
Military Medical Academy of S.M. Kirov
Email: tuostax@mail.ru
SPIN 代码: 5766-8003
candidate of medical sciences
俄罗斯联邦, Saint PetersburgAnna Rozhkova
Military Medical Academy of S.M. Kirov
Email: anna_rozhkova@mail.ru
ORCID iD: 0000-0002-5778-1237
therapist
俄罗斯联邦, Saint Petersburg参考
- Petrik GG, Pavlishhuk SA, Kosmacheva ED. Diabetes mellitus and cardiovascular complications: focus on hemostasis. Russian Journal of Cardiology. 2014;(3):114–118. (In Russ.). doi: 10.15829/1560-4071-2014-3-114-118
- Sergienko IV, Ansheles AA, Khalimov YuSh, et al. Kardiologicheskie aspekty sakharnogo diabeta 2 tipa. Moscow: Pero; 2018. 68 p. (In Russ.).
- Krjukov EV, Kuchmin AN, Umanskaja EP. The main pathogenetic mechanisms of hypercoagulation in diabetes and the possibility of its drug correction. Bulletin of the Russian Military Medical Academy. 2021;(2):165–174. (In Russ.). doi: 10.17816/brmma64995
- Salukhov VV, Gulyaev NI, Chepel’ AI, et al. Preventive antiplatelet therapy of ischemic heart disease complications in conditions of variability of platelet response. Bulletin of the National Medical and Surgical Center named after N.I. Pirogov. 2020;15(4):82–90. (In Russ.). doi: 10.25881/BPNMSC.2020.20.88.016
- Cosentino F, Grant PJ, Aboyans V, et al. 2019 Rekomendatsii ESC/EASD po sakharnomu diabetu, prediabetu i serdechno-sosudistym zabolevaniyam. Russian Journal of Cardiology. 2020;25(4):3839. (In Russ.). doi: 10.15829/1560-4071-2020-3839
- Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86. doi: 10.1136/bmj.324.7329.71
- Eikelboom JW, Hirsh J, Spencer FA, et al. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis. Chest. 2012;141(2):e89S–e119S. doi: 10.1378/chest.11-2293
- Bailey MA, Aggarwal R, Bridge KI, et al. Aspirin therapy is associated with less compact fibrin networks and enhanced fibrinolysis in patients with abdominal aortic aneurysm. J Thromb Haemost. 2015;13(5):795–801. doi: 10.1111/jth.12872
- Tehrani S, Antovic A, Mobarrez F, et al. High-dose aspirin is required to influence plasma fibrin network structure in patients with type 1 diabetes. Diabetes Care. 2012;35(2):404–408. doi: 10.2337/dc11-1302
- Ushkalova EA. Aspirin resistance: development mechanisms, diagnostic methods and clinical significance. Farmateca. 2006;(13):35–41. (In Russ.).
- Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2003;2(1):15–28. doi: 10.1038/nrd985
- Lordkipanidzé M. Advances in monitoring of aspirin therapy. Platelets. 2012;23(7):526–536. doi: 10.3109/09537104.2012.711865
- Cipollone F, Rocca B, Patrono C. Ciclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc. 2004;24(2):246–255.
- Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;26(336):195–198. doi: 10.1136/bmj.39430.529549
- Watala C, Pluta J, Golanski J, et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med (Berl.) 2005;83(2):148–158. doi: 10.1007/s00109-004-0600-x
- Russo I, Viretto M, Barale C, et al. High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets. Diabetes. 2012;61(11):2913–2921. doi: 10.2337/db12-0040
- Dillinger JG, Drissa A, Sideris G, et al. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. Am Heart J. 2012;164(4):600–606. doi: 10.1016/j.ahj.2012.06.008
- García Rodríguez LA, Hernández-Díaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001;52(5): 563–571. doi: 10.1046/j.0306-5251.2001.01476.x
- Bowman L, Mafham M, Stevens W, et al. ASCEND: A Study of Cardiovascular Events in Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. Am Heart J. 2018;198:135–144. doi: 10.1016/j.ahj.2017.12.006
- Capodanno D, Angiolillo DJ. Antithrombotic therapy in patients with chronic kidney disease. Circulation. 2012;125(21):2649–2661. doi: 10.1161/circulationaha.111.084996
- Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol. 2010;50(2):126–142. doi: 10.1177/0091270009343005
- Fork FT, Lafolie P, Tóth E, Lindgärde F. Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers. A gastroscopic study. Scand. J Gastroenterol. 2000;35(5):464–469. doi: 10.1080/003655200750023705
- Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008;118(18):1894–1909. doi: 10.1161/CIRCULATIONAHA.108.191087
- Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007;154(2):221–231. doi: 10.1016/j.ahj.2007.04.014
- Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108(7):2244–2247. doi: 10.1182/blood-2006-04-013052
- Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(16):1821–1830. doi: 10.1001/jama.2010.1543
- Htun P, Fateh-Moghadam S, Bischofs C, et al. Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J Am Soc Nephrol. 2011;22(4):627–633. doi: 10.1681/ASN.2010020220
- Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003;107(1):32–37. doi: 10.1161/01.cir.0000047060.60595.cc
- Serebruany VL, Malinin AI, Callahan KP, et al. Statins do not affect platelet inhibition with clopidogrel during coronary stenting. Atherosclerosis. 2001;159(1):239–241. doi: 10.1016/s0021-9150(01)00606-2
- Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909–1917. doi: 10.1056/NEJMoa1007964
- Wu ZK, Wang JJ, Wang T, et al. Clopidogrel resistance response in patients with coronary artery disease and metabolic syndrome: the role of hyperglycemia and obesity. J Geriatr Cardiol. 2015;12(4):378–382. doi: 10.11909/j.issn.1671-5411.2015.04.009
- Ferguson AD, Dokainish H, Lakkis N. Aspirin and clopidogrel response variability: review of the published literature. Tex Heart Inst J 2008;35(3):313–320.
- Dasgupta A, Steinhubl SR, Bhatt DL, et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am J Cardiol. 2009;103(10): 1359–1363. doi: 10.1016/j.amjcard.2009.01.342
- Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–1717. doi: 10.1056/NEJMoa060989
- Dedov II, Shestakova MV, Mayorova AYu, editors. Standards of specialized diabetes care. 10th ed. Moscow. 2021. 222 p. (In Russ.). DOI: doi: 10.14341/DM12802
- Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502. doi: 10.1056/NEJMoa010746
- Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19): 411–2420. doi: 10.1001/jama.288.19.2411
- Gori AM, Marcucci R, Migliorini A, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol. 2008;52(9): 734–739. doi: 10.1016/j.jacc.2008.05.032
- Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015. doi: 10.1056/NEJMoa0706482
- Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008;371(9621):1353–1363. doi: 10.1016/S0140-6736(08)60422-5
- Sanderson NC, Parker WAE, Storey RF. Ticagrelor: clinical development and future potential. Rev Cardiovasc Med. 2021;22(2):373–394. doi: 10.31083/j.rcm2202044
- Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057. doi: 10.1056/NEJMoa0904327
- James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010;122(11):1056–1067. doi: 10.1161/CIRCULATIONAHA.109.933796
- Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155–2166. doi: 10.1056/NEJMoa1409312
- Parker WA, Storey RF. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54. Heart. 2016;102(10):83–789. doi: 10.1136/heartjnl-2015-307858
- Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):1082–1115. doi: 10.1016/j.jacc.2016.03.513
- Bohne LJ, Johnson D, Rose RA, et al. The Association Between Diabetes Mellitus and Atrial Fibrillation: Clinical and Mechanistic Insights. Front Physiol. 2019;10:135. doi: 10.3389/fphys.2019.00135
- Rizzo MR, Sasso FC, Marfella R, et al. Autonomic dysfunction is associated with brief episodes of atrial fibrillation in type 2 diabetes. J Diabetes Complicat. 2015;29(1):88–92. doi: 10.1016/j.jdiacomp.2014.09.002
- Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 2016;37(38):2893–2962. doi: 10.1093/eurheartj/ehw210
- Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–272. doi: 10.1378/chest.09-1584
- Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962. doi: 10.1016/S0140-6736(13)62343-0
- Moiseev SV. Prevention of cardiovascular outcomes in diabetic patients with atrial fibrillation: direct oral anticoagulants or warfarin? Clinical Pharmacology and Therapy. 2019;28(3):5–13. (In Russ.). doi: 10.32756/0869-5490-2019-3-5-13
- Böhm M, Ezekowitz MD, Connolly J, et al. Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. J Am Coll Cardiol. 2015;65(23):2481–2493. doi: 10.1016/j.jacc.2015.03.577
- Del-Carpio Munoz F, Gharacholou SM, Munger TM, et al. Meta-Analysis of Renal Function on the Safety and Efficacy of Novel Oral Anticoagulants for Atrial Fibrillation. Am J Card. 2016;117(1):69–75. doi: 10.1016/j.amjcard.2015.09.046
- Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–1393. doi: 10.1093/eurheartj/ehy136
- Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Russian Journal of Cardiology. 2017;22(7):7–86. (In Russ.). doi: 10.15829/1560-4071-2017-7-7-86
- Redondo M, Caliezi C, Biasiutti FD, et al. Increased fibrin monomer plasma concentration in stable coronary artery disease in patients without oral anticoagulation. Atherosclerosis. 2001;157(2):417–422. doi: 10.1016/s0021-9150(00)00731-0
- Tosi F, Micaglio R, Sandri M, et al. Increased plasma thrombin potential is associated with stable coronary artery disease: An angiographically-controlled study. Thromb Res. 2017;155:16–22. doi: 10.1016/j.thromres.2017.04.021
- Corrado E, Rizzo M, Muratori I, et al. Association of elevated fibrinogen and C-reactive protein levels with carotid lesions in patients with newly diagnosed hypertension or type II diabetes. Arch Med Res. 2006;37(8):1004–1009. doi: 10.1016/j.arcmed.2006.06.005
- Festa A, Williams K, Tracy RP, et al. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation. 2006;113(14):1753–1759. doi: 10.1161/CIRCULATIONAHA.106.616177
- Gibson CM, Mega JL, Burton P, et al. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J. 2011;161(5):815–821.e6. doi: 10.1016/j.ahj.2011.01.026
- Connolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):205–218. doi: 10.1016/S0140-6736(17)32458-3
- Knuuti J. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Russian Journal of Cardiology. 2020;25(2):3757. (In Russ.). doi: 10.15829/1560-4071-2020-2-3757